News ArticleAlivus Life Sciences Posts ₹3,568 Million Net Profit in First Half of FY2026, Q2 Net Profit at ₹1,967 Million
Company reports ₹13,224 million revenue from operations for H1 ending September 30, 2026, with earnings per share of ₹29.06 for the period
Alivus Life Sciences Limited announced its unaudited financial results for Q2 and H1 ending September 30, 2026, reporting ₹1,967 million net profit in Q2 and ₹3,568 million in H1. Revenue from operations reached ₹6,820 million in Q2 and ₹13,224 million in H1, reflecting operational scale. Earnings per share stood at ₹16.02 (basic) for Q2 and ₹29.06 for H1, based on 245.54 million equity shares.
Alivus Life Sciences Limited
Financial Results
Alivus Life Sciences Limited has reported its unaudited financial results for the second quarter and half year ended September 30, 2026, posting a net profit of ₹1,967 million for the quarter and ₹3,568 million for the half year, supported by revenue growth.
For Q2 FY2026, the company recorded revenue from operations of ₹6,819.87 million, while the half year revenue totaled ₹13,224.01 million.
Total expenses for Q2 were ₹4,399.30 million and ₹8,905.22 million for H1, resulting in a profit before tax of ₹2,619.74 million for Q2 and ₹4,741.97 million for the half year.
The company's basic earnings per equity share stood at ₹16.02 for Q2 and ₹29.06 for H1, based on a share capital of ₹245.54 million issued.
Other comprehensive income after tax was ₹8.98 million for Q2 and ₹12.06 million for H1, contributing to total comprehensive income of ₹1,976.43 million and ₹3,580.27 million respectively.
The unaudited balance sheet as of September 30, 2026, showed total assets of ₹43,419.36 million and equity of ₹36,312.86 million, indicating solid financial positioning.
Highlights
- Q2 2026 net profit: ₹1,967.45 million
- H1 2026 net profit: ₹3,568.21 million
- Q2 revenue from operations: ₹6,819.87 million
- H1 revenue from operations: ₹13,224.01 million
- Basic earnings per share for Q2: ₹16.02 and for H1: ₹29.06
- Total assets as of Sept 30, 2026: ₹43,419.36 million
Key Data Snapshot
Financial performance
- Reported Q2 2026 net profit of ₹1,967.45 million and half year net profit of ₹3,568.21 million.
- Revenue from operations grew to ₹6,819.87 million in Q2 and ₹13,224.01 million for H1 2026.
- Total expenses were ₹4,399.30 million for Q2 and ₹8,905.22 million for the half year.
- Basic earnings per share were ₹16.02 for Q2 and ₹29.06 for H1, based on 245.54 million equity shares of ₹2 each.
- Other comprehensive income after tax contributed ₹8.98 million in Q2 and ₹12.06 million for H1, leading to total comprehensive income of ₹1,976.43 million and ₹3,580.27 million respectively.
Regulatory and governance context
- Results were unaudited and reviewed as per SEBI (LODR) regulations.
- Board meeting on October 29, 2026, approved the unaudited financial results for Q2 and H1 ending September 30, 2026.
- Limited review report by auditor accompanied the financial results.
- Results were disclosed to BSE and NSE and hosted on the company website www.alivus.com.
Background and context
- Company formerly known as Glenmark Life Sciences Limited, now renamed Alivus Life Sciences Limited.
- Corporate office located at Technopolis Knowledge Park, Mumbai.
- Registered office based in Solapur, Maharashtra, India.
Highlights
- Q2 2026 net profit: ₹1,967.45 million
- H1 2026 net profit: ₹3,568.21 million
- Q2 revenue from operations: ₹6,819.87 million
- H1 revenue from operations: ₹13,224.01 million
- Basic earnings per share for Q2: ₹16.02 and for H1: ₹29.06
- Total assets as of Sept 30, 2026: ₹43,419.36 million
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
More News on Financial Results
View allLatest corporate announcements and market updates in Financial Results.
Indegene Limited Announces Unaudited Consolidated and Standalone Results for Q2 and H1 Ending September 30, 2026
Indegene Limited approved its unaudited consolidated and standalone financial results for the second quarter and half year ended September 30, 2026, alongside approving allotments under RSU and ESOP schemes and key personnel resignations during its board meeting on October 29, 2026.
Read Full Story
Timken India Limited Achieves Rs 2,311.94 Million Net Profit for First Half of FY 2026-27
Timken India Limited reported a net profit after tax of Rs 2,311.94 million for the half year ended September 30, 2026, with revenue from operations totaling Rs 18,983.82 million, as per its unaudited standalone financial results approved by the Board on October 29, 2026.
Read Full Story
Deepak Nitrite Limited Approves Unaudited Financial Results for Q2 and H1 September 2026
Deepak Nitrite Limited's Board approved the unaudited standalone and consolidated financial results for the quarter and half year ended 30th September 2026, with a limited review conducted by Deloitte Haskins & Sells LLP.
Read Full Story
